SS

Saket Shukla

Active Director Director DIN 10185013
DIN 10185013 First appointment May 2023 Primary industry Outsourcing
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value •••• Premium profile

About Saket Shukla

Data last updated:

Saket Shukla is a Director at Samben Pharma Private Limited (since 2023). The company operates in Outsourcing. Samben Pharma Private Limited reported revenue of ₹9.49 Cr (FY 2025).

DIN 10185013
Primary Designation Director
Industry Outsourcing
First Appointment 31 May 2023
Oldest Company Age 3 yrs
Largest company Samben Pharma Private Limited · ₹9.49 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Samben Pharma Private Limited U46497UP2023PTC183150
Director31 May 20232023₹9.49 Cr (FY 2025)Active

Board colleagues of Saket Shukla

NameDINCompanyDesignation
Siddharth Shukla10185012Samben Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Samben Pharma Private Limited
Premium access

Shareholding and investment profile for Saket Shukla

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Saket Shukla

Saket Shukla currently holds 1 directorship: Samben Pharma Private Limited (Director, since 31 May 2023, revenue ₹9.49 Cr (FY 2025)).

Saket Shukla was first appointed on 31 May 2023 as Director at Samben Pharma Private Limited.

The current boards of Saket Shukla's companies include Siddharth Shukla (Samben Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available